PODD

Business Context and Reporting Period

Company: Insulet Corporation (Insulet)

Reporting Period: Quarter ended March 31, 2011 (Form 10-Q)

Business Overview: Insulet develops, manufactures, and markets the OmniPod Insulin Management System, a wearable insulin infusion device for insulin-dependent diabetes. The company operates in a single segment. In Q1 2011, the company expanded its international distribution footprint, entering into an agreement with GlaxoSmithKline (GSK) for exclusive distribution in Canada and continuing distribution in seven European markets via Ypsomed.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 36% year-over-year, driven by continued adoption of the OmniPod System in the U.S. and international markets.
• Margin Expansion: Gross margin improved by 8 percentage points to 48%. This was achieved despite a 19% increase in cost of revenue, as revenue grew faster due to production efficiencies and a lower bill of materials.
• Reduced Losses: Net loss decreased 32% to $9.8 million. The operating loss narrowed by 32% to $7.3 million.
• Interest Expense: Net interest expense decreased significantly (from $3.8 million to $2.6 million) following the repayment of the Facility Agreement in December 2010, eliminating associated cash and non-cash interest costs.
• Operating Expenses: Total operating expenses rose 9% to $20.8 million. Increases were seen in R&D (19%), Sales & Marketing (8%), and G&A (4%), primarily due to personnel additions, stock-based compensation, and materials for next-generation product development.

Guidance, Outlook, and Risks

• Outlook: Management expects revenue to continue increasing in 2011 due to new patient acquisition in the U.S. and expansion in Europe and Canada. R&D spending is expected to decrease slightly in 2011 as development on the next-generation OmniPod nears completion. Sales and marketing expenses are expected to increase slightly to support growth.
• Liquidity: The company believes its cash balance of $104.5 million, combined with expected product sales, is sufficient to meet operating and debt service requirements for at least the next 12 months.
• Debt Obligations: The company has $85.0 million principal of 5.375% Convertible Senior Notes due June 2013. These notes are convertible at approximately $21.35 per share.
• Risks:
  • Legal Proceedings: Becton, Dickinson and Company (BD) filed a patent infringement lawsuit in August 2010. Insulet believes it has meritorious defenses and does not expect a material adverse impact, though litigation outcomes are uncertain.
  • Reimbursement: Success depends heavily on third-party payor reimbursement rates and policies.
  • Manufacturing: Reliance on a third-party supplier (Flextronics) in China for manufacturing.

Investor Verification Checklist

• Reimbursement Status: Verify the status of reimbursement approvals in new international markets (Canada via GSK, remaining European markets via Ypsomed) as these are prerequisites for revenue recognition.
• Patent Litigation: Monitor the status of the BD patent infringement lawsuit for any updates on injunctions or damages.
• Debt Conversion: Review the terms of the 5.375% Convertible Notes due 2013, specifically the conversion price ($21.35) relative to current stock prices to assess potential dilution.
• Next-Gen Product: Track progress on the next-generation OmniPod System, as management cites this as a key driver for future cost reductions and profitability.
• Cash Burn: Monitor the rate of cash consumption against the $104.5 million cash balance to ensure the 12-month liquidity runway remains valid.